Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart - A Multi-Center Non-Inferiority Placebo-Controlled Observer-Blinded Phase 2 Randomized Controlled Trial

NCT07275060 is registered in ClinicalTrials.gov with Canadian Immunization Research Network as lead sponsor.

NCT NCT07275060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07275060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart - A Multi-Center Non-Inferiority Placebo-Controlled Observer-Blinded Phase 2 Randomized Controlled Trial
Lead sponsor
Canadian Immunization Research Network
Phase
Phase 4
Overall status
Active, not recruiting
Start date
October 14, 2025
Completion date
September 30, 2027
Enrollment
312 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

avian influenza, avian influenza a virus, h5n1 influenza, h5n1 virus